Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Hodgkin's lymphoma

This page shows the latest Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics claims key US approval for Adcetris

Seattle Genetics claims key US approval for Adcetris

According to the FDA, there were around 8, 260 people diagnosed with Hodgkin’s lymphoma last year. ... First approved in 2011 for Hodgkin’s lymphoma patients who had failed a stem cell transplant, Adcetris has now picked up five indications.

Latest news

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    The majority of patients treated with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo will receive fewer injections after the FDA cleared a four-weekly dosing regimen for the drug. ... and classical Hodgkin’s lymphoma, said BMS in a statement.

  • FDA turns down Celgene’s filing for multiple sclerosis drug FDA turns down Celgene’s filing for multiple sclerosis drug

    Celgene has had a difficult few months, with the latest knock coming after its blood cancer blockbuster Revlimid (lenalidomide) failed to hit the mark in non-Hodgkin’s lymphoma, the failure ... of Crohn’s disease candidate GED-0301, and lacklustre

  • Takeda bags EU approval for Adcetris in lymphoma Takeda bags EU approval for Adcetris in lymphoma

    It filed for US approval in CTCL last August. In Europe, Adcetris is also approved for CD30-positive Hodgkin’s lymphoma following autologous stem cell transplant (ASCT), or following at least ... There are more new indications on the way, and Takeda

  • Seattle Genetics' Adcetris earns FDA priority review status Seattle Genetics' Adcetris earns FDA priority review status

    Siegall added: “The FDA’s filing of our supplemental BLA with priority review represents a significant milestone in our goal to redefine the frontline treatment of advanced Hodgkin lymphoma.”. ... Although the current standard of care can result in

  • CAR-T therapies show long-term benefits in lymphoma CAR-T therapies show long-term benefits in lymphoma

    CAR-T therapies show long-term benefits in lymphoma. Novartis’Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients. ... One-year results from the ZUMA-1 trial of Gilead’s Yescarta (axicabtagene ciloleucel)

More from news
Approximately 19 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    The significance of this lays in the evolving nature of Takeda's portfolio. “ ... Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Quick links

Infographics

Multimedia